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Abstract The presynaptic protein alpha-synuclein has
received much attention because its gain-of-function is
associated with Parkinson’s disease. However, its physio-
logical function is still poorly understood. We studied brain
regions of knock-out mice at different ages with regard to
consistent upregulations of the transcriptome and focused
on glyoxalase I (GLO1). The microarray data were con-
firmed in qPCR, immunoblot, enzyme activity, and
behavior analyses. GLO1 induction is a known protective
cellular response to glucose stress, representing efforts to
decrease toxic levels of methylglyoxal (MG), glyoxal and
advanced glycation endproducts (AGEs). Mass spectrom-
etry quantification demonstrated a ubiquitous increase in
MG and fructosyl-lysine as consequences of glucose tox-
icity, and consistent enhancement of certain AGEs. Thus,
GLO1 induction in KO brain seems insufficient to prevent
AGE formation. In conclusion, the data demonstrate GLO1
expression and glycation damage to be induced by alpha-
synuclein ablation. We propose that wild-type alpha-syn-
uclein modulates brain glucose metabolism.
Keywords Alpha-synuclein deficiency 
Transcriptome microarray  Glyoxalase I 
Advanced glycation endproducts  Glucose metabolism
Non-standard abbreviations
3-DG 3-deoxyglucosone
3DG-H Hydroimidazolones derived from
3-deoxyglucosone
3-NT 3-nitrotyrosine
AGE Advanced glycation endproduct
CE Collision energy
CEL Ne-carboxyethyl-lysine
CMA Nx-carboxymethyl-arginine
CMC S-carboxymethyl-cysteine
CML Ne-carboxymethyl-lysine
CV Cone voltage
DETAPAC Diethylenetriamine penta-acetic acid
DT Dityrosine
FBPase Fructose-1, 6-bisphosphatase
FL Fructosyl-lysine
Gabrg2 Gamma-aminobutyric acid (GABA-A)
receptor subunit gamma 2
GEO Gene Expression Omnibus
G-H1 Hydroimidazolones derived from glyoxal
GLO1 Glyoxalase 1
LC–MS/MS Liquid chromatography-tandem mass
spectrometry
LOD Limit of detection
MetSO Methionine sulfoxide
MG Methylglyoxal
MG-H1 Hydroimidazolones derived from
methylglyoxal
MOLD MG-derived lysine dimer
NFK N-formylkynurenine
A. Kurz  G. Auburger  S. Gispert (&)
Department of Neurology, Section Molecular Neurogenetics,
Bldg. 89, Goethe University Medical School,
Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
e-mail: gispert-sanchez@em.uni-frankfurt.de
N. Rabbani  P. Thornalley
Clinical Sciences Research Institute, Warwick Medical School,
University of Warwick, University Hospital,
Coventry CV2 2DX, UK
M. Walter  M. Bonin
Institute of Medical Genetics, Eberhard Karls University,
Tu¨bingen, Germany
Cell. Mol. Life Sci. (2011) 68:721–733
DOI 10.1007/s00018-010-0483-7 Cellular and Molecular Life Sciences
pnd Postnatal day
qPCR Quantitative real-time RT-PCR
RIPA Radio immuno precipitation assay
SNCA Alpha-synuclein
Tbp TATA binding protein
TCA Trichloroacetic acid
UPLC Ultrahigh pressure liquid chromatography
Introduction
Alpha-synuclein was initially described as a component of
the extracellular protein aggregates characteristic for Alz-
heimer’s disease (AD) [1]. Later, missense mutations and
elevated gene dosage of the alpha-synuclein gene SNCA
were found to cause rare autosomal dominant variants of
Parkinson’s disease (PD) with early manifestation [2, 3]. In
the frequent sporadic old-age variant of PD, wild-type
(WT) alpha-synuclein acquires gain-of-function properties,
undergoes protein aggregation and forms cytoplasmic
inclusions named Lewy bodies in the affected neurons [4].
With advancing age, this pathogenic process advances
from the brainstem via the midbrain to involve eventually
all cerebral regions including the primary neocortex [5].
This regional specificity may result from different meta-
bolic demands, since most Parkinson-associated genes like
alpha-synuclein are expressed quite ubiquitously. The
affected tissue is characterized by a loss of glutathione and
oxidative stress since presymptomatic stages [6]. With age,
mutations in the mitochondrial genome accumulate, with
impairment of respiratory complex I activity [7]. Mito-
chondrial dysfunction and alpha-synuclein aggregation
characterize the degenerating neurons after a disease
course of more than 30 years [8], while identical mutation
effects have little degenerative effects after the 2-year
lifespan of mouse models with overexpression of SNCA. In
living patients, the neurodegenerative process of PD can be
monitored through the documentation of reduced glucose
utilization in affected brain regions by positron emission
tomography [9].
However, the physiological function of alpha-synuclein
is not well understood. Its expression is mainly in neurons
and its localization is usually presynaptic [10]. Alpha-
synuclein was implicated in Golgi trafficking by comple-
mentation studies in yeast and C. elegans [11–14] and
found in association with synaptic vesicles [15]. It was
proposed to act as chaperone or inhibitor of the SNARE
complex responsible for vesicle fusion and neurotransmit-
ter release [16, 17]. In mice with alpha-synuclein loss-of-
function (SNCA-KO), a reduction of synaptic vesicles and
neurotransmitter levels [18–21], altered neurotransmitter
release [22, 23], selective changes in synaptic signaling
proteins [24], altered synaptic plasticity [25], pathological
lipid composition and respiratory activity of mitochondria
[26] were reported. Thus, brain alpha-synuclein appears to
exhibit important functions for synaptic transmission and
maintenance, but the molecular interactions and mecha-
nisms remain largely undefined.
In order to gain additional molecular insights into the
physiological functions of alpha-synuclein in the aging
nervous system, we employed young and old SNCA-KO
mice to document the transcriptional profile of two quite
homogeneous brain regions (striatum and cerebellum). An
upregulation of glyoxalase I (GLO1), a highly conserved
enzyme known to protect cells from glucose toxicity, was
observed consistently. This induction was found insuffi-
cient to protect the tissue completely against glycation
damage. Overall, the data suggest a prominent alteration of
glucose metabolism in mouse brain by SNCA ablation.
Materials and methods
Animals and housing
Alpha-synuclein-deficient (knock-out, KO) mice with a
targeted replacement of exons 4 and 5 of the SNCA gene
[19] were compared to wild-type (WT) animals with the
corresponding 129S6/SvEvTac background.
Mice were housed in Type II L cages (365 9
207 9 140 mm, floor area 530 cm2; IVC-based) in the
same animal room (where the environmental temperature
was maintained between 20 and 24C, humidity: 55 ±
10%) under 12/12 h light/dark cycle with food and water
ad libitum.
All experiments employing mice were performed in
compliance with the European Communities Council
Directive of 24 November 1986 (86/609/EEC) and the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Transcriptome analyses
Three age groups were employed: mouse pups at the age of
postnatal day 7 (pnd 7), young adult mice at the age of
6 months and old mice of at least 19 months of age. Fol-
lowing cervical dislocation of young adult and old mice,
the brain was dissected into brainstem, midbrain, cerebel-
lum, and striatum (dorsal and ventral striatum as a tissue
block). In case of the mouse pups, the brain was dissected
into both hemispheres. Immediately after dissection, the
tissues were frozen in liquid nitrogen and stored at -80C
until further analyses.
The data discussed in this publication have been
deposited in NCBI’s Gene Expression Omnibus [27] and
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are accessible through GEO series accession number
GSE19534.
Transcriptome survey via oligonucleotide microarrays
From the brains of adult (6 months) versus old (21 months)
male mice, striatal (n = 3 mutant vs. n = 3 wild-type) and
cerebellar (n = 3 vs. n = 4) tissue was dissected, both for
KO mice and for WT control animals. Double-stranded
cDNA synthesized from 1 lg of total RNA was linearly
amplified and biotinylated using the One-Cycle Target
Labeling Kit (Affymetrix; Santa Clara, CA, USA)
according to the manufacturer’s instructions.
Labeled and fragmented cRNA (15 lg) was hybridized
to MOE430 2.0 GeneChip arrays (Affymetrix). After
hybridization, the arrays were washed and stained in a
Fluidics Station 450 (Affymetrix) with the recommended
washing procedure. Biotinylated cRNA bound to target
molecules was detected with streptavidin-coupled phy-
coerithrin, biotinylated anti-streptavidin IgG antibodies and
again streptavidin-coupled phycoerithrin according to the
protocol. Arrays were scanned using the GCS3000 Gene-
Chip scanner (Affymetrix) and GCOS 1.4 software.
Scanned images were subjected to visual inspection to
control for hybridization artifacts and proper grid
alignment.
Linear models were applied to define the influence of
the factor genotype on the transcriptome. For quality
control, Genespring 7.3 (Agilent Technologies; Bo¨blingen,
Germany) and Expression Console (Affymetrix) were
used. The data was mathematical-statistically assessed,
visualized, and functionally correlated by employing the
software platform R (version 2.5.0) and Bioconductor
2.0.8 [28] with the packages ‘‘affy’’ [29] and ‘‘limma’’
[30, 31] as well as the panther website (http://www.
pantherdb.org).
Initially, the expression data from all chips were nor-
malized with the RMA (Robust Multichip Average)
method to yield log2-transformed signal values. Global
gene expression was compared between chips using
scatter plots and Pearson’s R correlation coefficients. The
signal values were then averaged for the individual sub-
groups and differences in expression level were calculated
in log2 space (M values). Differences between subgroups
were extracted as contrasts and analyzed with the mod-
erated F test (empirical Bayes method) including a
correction step for multiple testing with the 5%-FDR-
based method of Benjamini and Hochberg. To attribute
significant regulations to individual genes, a decision
matrix was generated based on the function decide tests
within the Limma option nestedF, where significant up- or
downregulations are represented by values of 1 or -1,
respectively.
Transcript level assays via qPCR
Total RNA was extracted from brain hemispheres derived
from mouse pups and from brainstem and midbrain derived
from adult male mice with TRIZOL (Invitrogen; Karlsruhe,
Germany) and digested with DNase (amplification grade I;
Invitrogen) following the manufacturer’s instructions. In
case of the striata derived from 19-month-old male mice,
RNeasy Lipid Tissue Mini Kit (Qiagen; Hilden, Germany)
was used for RNA extraction. Then, 2 lg of DNase-treated
RNA were reverse-transcribed in a 36-ll reaction, using
pd(N)6 and NotI-d(T)18 primers (First Strand cDNA Syn-
thesis Kit; Amersham Biosciences; Freiburg, Germany).
For validation of Glo1 transcript levels, all qPCR reac-
tions were carried out in a total volume of 20 ll containing
5 ll cDNA template, 10 ll 29 TaqMan Universal Master
Mix (Applied Biosystems; Darmstadt, Germany) and 1 ll
209 TaqMan gene expression assay (Applied Biosys-
tems) on an ABI Prism 5700 sequence detection system
(SDS5700; Applied Biosystems).
Expression levels of the transcript for TATA binding
protein (Tbp) were used for the normalization of Glo1
transcript levels. Expression changes were analyzed with the
2-DDCt method [32]. The following TaqMan assays were
employed: Mm00844954_s1 (Glo1) and Mm00446973_m1
(Tbp).
Immunoblots
Following tissue homogenization with RIPA buffer
(50 mM TRIS pH 8.0, 150 mM NaCl, 1% Triton X-100,
0.5% Na-deoxycholate, 0.1% SDS) supplemented with
complete protease inhibitor cocktail (Roche; Penzberg,
Germany), samples were incubated at 4C, rotating for
20 min. Brain tissue homogenates were centrifuged for
15 min at 4,500 9 g and 4C and supernatants collected.
Then 20 lg of protein were separated in 10% tris–glycine
polyacrylamide and transferred onto a PVDF membrane
(Bio-Rad; Hercules, CA, USA). Membranes were blocked
with 5% fat-free milk in phosphate buffered saline (PBS)/
0.1% Tween (T) for 1 h at room temperature (RT) and
incubated with the primary antibody overnight at 4C (anti-
GLO1 (T-16), 1:200 dilution, Santa Cruz Biotechnology
(Santa Cruz, CA, USA), #sc-50732 or anti-beta-actin,
1:10,000 dilution, Sigma-Aldrich (Hamburg, Germany),
#A-5441 for normalization) in PBS/T, washed three times
with PBS/T and incubated with the secondary antibody
(horseradish peroxidase conjugated anti-goat IgG, 1:30,000
dilution, Santa Cruz Biotechnology, #sc-2020 or horse-
radish peroxidase-linked anti-mouse 1:15,000 dilution,
Amersham Biosciences, #NA931V) for 1 h at RT. After
washing, the secondary antibody was detected with a
chemiluminescent substrate (SuperSignal West Pico
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Chemiluminescent; Thermo Fisher Scientific; Rockford,
IL, USA). Densitometric analyses utilized TotalLab soft-
ware (Amersham Biosciences).
Assay of glyoxalase 1 activity
Flash-frozen mouse brain tissue (50–100 mg wet weight)
was homogenized in 400 ll 10 mM sodium phosphate
buffer, pH 7.4 and 4C, and centrifuged (20,000 9 g,
30 min, 4C). The supernatant was used as the cytosolic
extract for determination of GLO1 activity and protein
content (Bradford method). The activity of GLO1 is
determined by measuring the initial rate of formation of
S-D-lactoylglutathione from the hemithioacetal formed non-
enzymatically from MG and reduced glutathione. This was
conveniently determined by following the increase in
absorbance at 240 nm for which De240 = 2.86 mM
-1 cm-1
[33]. Hemithioacetal was prepared by pre-incubation of
methylglyoxal (2 lmol) with glutathione (2 lmol) at 37C
for 10 min in sodium phosphate buffer (50 mM, pH 6.6,
998 ll). The tissue extract (2 ll) was added and the absor-
bance at 240 nm monitored with time for 5 min. The activity
of GLO1 is deduced from the initial increase in absorbance,
corrected for homogenization buffer blank. GLO1 activity is
given in units per mg protein where one unit of GLO1
activity is the amount of enzyme which catalyzes the for-
mation of 1 lmol of S-D-lactoylglutathione per minute under
assay conditions.
Measurement of dicarbonyls in brain tissue
Dicarbonyl metabolites glyoxal, methylglyoxal (MG) and
3-deoxyglucosone (3-DG) were determined by derivati-
zation with 1,2-diaminobenzene and quantitation of the
resulting quinoxaline adducts by stable isotopic dilution
analysis liquid chromatography-tandem mass spectrometry
(LC–MS/MS). Brainstem/midbrain and cerebral cortex
(10–20 mg wet weight) of 18-month-old KO and WT
mice were homogenized in 10% ice-cold trichloroacetic
acid (TCA); 25 ll. Stable isotopic standards ([13C2]gly-
oxal, [13C3]methylglyoxal and [
13C6]3-DG; 2 pmol) were
added to the samples, mixed, and then centrifuged
(20,000 9 g, 30 min, 4C). The supernatant (35 ll) was
removed, sodium azide (6%, 5 ll) added, and then finally
10 ll 0.5 mM 1,2-diaminobenzene solution containing
0.5 mM diethylenetriamine penta-acetic acid (DETAPAC)
and 0.2 M HCl were added. The samples were incubated
in the dark for 4 h. Calibration standards were prepared
and derivatized concurrently containing 2 pmol isotopic
standards and 0–10 pmol glyoxal, methylglyoxal and
3-deoxyglucosone.
Samples were analyzed by LC–MS/MS with a Waters
Acquity ultrahigh pressure liquid chromatography (UPLC)
system linked to a Waters Quattro Premier XE tandem
mass spectrometer. The column was a BEH C18 1.7-lm
particle size, 2.1 9 100 mm with a guard column
(5 9 2.1 mm). The mobile phase was 0.1% trifluoroacetic
acid in water with a linear gradient of 0 to 50% acetonitrile
over 10 min; the flow rate was 0.2 ml/min. For mass
spectrometric detection, the capillary voltage was 0.6 kV,
the ion source temperature 120C, the desolvation gas
temperature 350C, and cone and desolvation gas flows
140 and 900 l/h, respectively. The retention time (Rt), mass
transitions (molecular ion [ fragmentation) for analyte and
internal standard, collision energy (CE), cone voltage
(CV), limit of detection (LOD), and analytical recovery
(%) for derivatized analytes, 3-DG, glyoxal and methyl-
glyoxal and were, respectively: Rt = 5.8, 7.3 and 7.9 min;
mass transitions for analyte 235.2 [ 199.0, 131.0 [ 77.1
and 145.0 [ 77.1 Da and internal standards 241.2 [ 205.0,
133.0 [ 77.1 and 148.0 [ 77.1 Da; CE = 16, 28 and
28 eV; CV = 21, 24 and 24 V; LOD = 34, 32 and 8 fmol;
and analytical recovery 76, 99, and 94%.
Determination of protein glycation, oxidation,
and nitration adducts
Protein glycation, oxidation, and nitration adduct residues
of protein extracts from brainstem/midbrain as well as
cortex were determined by stable isotopic dilution analysis
liquid chromatography with tandem mass spectrometric
detection (LC–MS/MS) after exhaustive enzymatic
hydrolysis [34].
Analytes determined were: early glycation adduct
Ne-fructosyl-lysine (FL); advanced glycation endproducts
(AGEs)—Ne-carboxymethyl-lysine (CML), Ne-carboxy-
ethyl-lysine (CEL), hydroimidazolones derived from
glyoxal, methylglyoxal and 3-deoxyglucosone (G-H1, MG-
H1 and 3DG-H, respectively), pentosidine, Nx-carboxy-
methyl-arginine (CMA), S-carboxymethyl-cysteine (CMC)
and MG-derived lysine dimer (MOLD); oxidation adducts—
methionine sulfoxide (MetSO), dityrosine (DT) and
N-formylkynurenine (NFK); the nitration adduct 3-nitroty-
rosine (3-NT); and related amino acids—lysine (lys),
arginine (arg), methionine (met), tyrosine (tyr), and trypto-
phan (trp).
Protein extracts prepared for GLO1 activity measure-
ment (0.2–5 mg protein) were washed by four cycles of
dilution to 500 ll and concentration to 50 ll in water over
a 10-kDa cut-off microspin filter and 100 lg of protein
were hydrolyzed exhaustively by sequential addition of
pepsin, pronase E, and aminopeptidase with prolidase as
described [35]. Analytes were detected by electrospray-
positive ionization multiple-reaction monitoring LC–MS/
MS and quantified by stable isotopic dilution analysis as
described with minor modifications [36].
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Pentosidine was determined by concurrent fluorescence
detection and quantified by reference to a calibration curve
response of authentic standard. LC–MS/MS and fluores-
cence detection was performed with a Waters Acquity
UPLC system with Acquity fluorescence detector and
Quattro Premier XE tandem mass spectrometer.
Open field test
Spontaneous motor activity was recorded over a period of
5 min using the parameters constituting the BBB score [37]
by measuring horizontal and vertical interruption of infra-
red beams in a 20 9 20 cm open field arena of the DigiScan
activity monitor (Omnitech Electronics; Columbus, OH,
USA).
Statistical analysis
Statistical analyses of the data derived from qPCRs,
immunoblots, enzyme activity assays, mass spectrometry
measurements of AGEs/oxidative markers, and open field
behavior assessments were performed via Prism 3 software
(GraphPad Software; La Jolla, CA, USA) using unpaired
two-tailed t tests. Data are presented as mean ± SEM. In
the figures, significant differences were illustrated with
asterisks (*p \ 0.05; **p \ 0.01; ***p \ 0.001).
Results
Brain transcriptome profile reveals strong upregulation
of Glo1
A genome-wide transcriptome analysis in striatum and
cerebellum of KO and age-/sex-matched WT mice was
performed to gain hypothesis-free insight into the physio-
logical function of the presynaptic protein alpha-synuclein.
For optimal signal-noise separation in light of the small
expression changes to be expected in complex brain tissue,
we maximized consistency criteria by employing 26
Affymetrix oligonucleotide microarray chips to compare
13 KO versus 13 WT brain tissue extracts. To represent
brain tissue known to be involved in PD, we chose the
striatum. To represent brain regions known for maximal
resistance to PD in spite of high alpha-synuclein expres-
sion, we chose cerebellar tissue. Given the importance of
age for synaptic plasticity and learning as well as for PD,
young adult animals at the age of 6 months and old animals
at the age of 21 months were employed.
Overall, we found the gene expression pattern to be very
similar for both genotypes, with only a few specific tran-
scripts showing dysregulation both in striatum and
cerebellum of young as well as old KO animals. Six genes
showing decreased expression were reported in a separate
manuscript [38]. This paper is focused on upregulated
transcripts, reporting for the first time six other non-anon-
ymous coding sequences exhibiting consistently increased
expression (Table 1; in alphabetical order): gamma-ami-
nobutyric acid (GABA-A) receptor subunit gamma 2
(Gabrg2; up to 1.47-fold), glyoxalase I (Glo1, up to 2.26-
fold), ISY1 splicing factor homolog (S. cerevisiae) (Isy1,
up to 1.88-fold), potassium channel modulatory factor 1
(Kcmf1, up to 1.6-fold), polymerase (DNA-directed) epsi-
lon 4 subunit p12 (Pole4, up to 4.16-fold) and cytotoxic
granule-associated RNA binding protein 1 (Tia1; up
to 14.98-fold). Interestingly, we observed a significant
upregulation of Gabrg2 upon analysis of the oligonucleo-
tide 1418177_at, but a significant downregulation of
Gabrg2 upon analysis of oligonucleotide 1437147_at [38].
A systematic database inquiry showed that the two
oligonucleotide spots onto the Affymetrix microarray rep-
resent different isoforms of Gabrg2: Affymetrix spot
#1418177_at does not distinguish the Gabrg2 isoforms 1
and 2, while Affymetrix spot #1437147_at represents only
the short isoform 2.
The increases of Glo1 as well as Pole4 transcripts were
the only upregulations detected consistently by several
different oligonucleotide spots (Table 1). These two tran-
scripts may reflect glucose stress and DNA damage
occurring in response to alpha-synuclein deficiency. Fur-
ther validation studies were focused on glyoxalase I in
view of its consistency and the availability of tools for
functional studies.
Independent qPCR analyses confirm significant
increases for Glo1
To extend the transcriptome survey with an independent
technique in further brain regions and ages, qPCR analyses
(Table 2) were performed using RNA extracts from addi-
tional animals. The elevation of Glo1 transcript levels at age
19 months was also detected in striatum with a factor of 2.72
(±0.33)-fold (n = 5/genotype; p = 0.0013). At the younger
age of 6 months in cerebellum, brainstem, midbrain and
cortex, increases of 1.83 (±0.13)-fold (n = 4/KO and
n = 3/WT; p = 0.0153), 1.95 (±0.04)-fold (n = 4/geno-
type; p = 0.0008), 1.74 (±0.07)-fold (n = 4/genotype;
p = 0.0033) and 1.60 (±0.08)-fold (n = 5/genotype;
p = 0.0090) were documented, respectively. At postnatal
day 7 (pnd7) in complete brain hemispheres, an increase by
2.17 (±0.10)-fold (n = 4/genotype; p \ 0.0001) was
detected. Thus, the data indicate an early, ubiquitous, and
constant upregulation of Glo1 transcript levels throughout
the brain, without tissue specificity or temporal dynamics.
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Immunoblot analysis confirms strong increases
for GLO1 protein in brain
To investigate whether the elevated Glo1 transcript levels
are translated to GLO1 protein levels, we performed
immunoblot analysis (Fig. 1) employing protein extracts
from striatum of additional KO and WT mice at age
19 months. Concordant with our previous investigations
on transcript level via microarray and qPCR, a signifi-
cant and strong increase of GLO1 protein levels by
3.26 (±0.32)-fold (n = 5/genotype; p = 0.0003) was
observed.
GLO1 enzyme activity and dicarbonyl contents
To validate the biological role of increased GLO1
expression, enzymatic activity of GLO1 was assessed in
brainstem/midbrain and cortex of old WT and KO mice.
GLO1 activity was increased 49% in the brainstem/mid-
brain of KO mice with respect to WT controls (Fig. 2a;
p \ 0.05) and 94% in cortex of KO mice with respect to
WT controls (Fig. 2b; p \ 0.001). The concentration of the
GLO1 substrate glyoxal (Fig. 2c, d) was similar in brain-
stem/midbrain and cortex of KO versus WT mice
(1.25 ± 0.16 vs. 1.32 ± 0.27 nmol/g wet weight) whereas
Table 1 Global transcriptome analysis in the brain of SNCA-deficient mice
Affymetrix
spot ID
Gene
symbol
Gene name Fold expression change
(KO versus WT)
Gene function References
Cerebellum Striatum
Young Old Young Old
1418177_at Gabrg2 Gamma-aminobutyric acid
(GABA-A) receptor, subunit
gamma 2
1.42 1.47 1.30 1.27 Synaptic transmission;
GABA signaling pathway
[63]
1451240_a_at Glo1 Glyoxalase 1 2.06 2.14 2.09 1.83 Carbohydrate metabolism; [36, 43, 64]
1424108_at Glo1 2.10 2.26 1.95 1.81 Detoxification of
methylglyoxal
1436070_at Glo1 1.62 1.64 1.53 1.50
1424109_a_at Glo1 1.95 2.11 1.88 1.68
1459728_at Isy1 ISY1 splicing factor homolog
(S. cerevisiae)
1.57 1.61 1.88 1.71 mRNA processing [65]
1418694_at Kcmf1 Potassium channel modulatory
factor 1
1.53 1.51 1.45 1.60 Protein ubiquitination [66]
1444739_at Pole4 Polymerase (DNA-directed)
epsilon 4, p12 subunit
4.16 2.58 3.85 3.08 DNA replication; [67, 68]
1423371_at Pole4 1.57 1.51 1.31 1.28 DNA repair
1431708_a_at Tia1 Cytotoxic granule-associated
RNA binding protein 1
13.54 8.07 14.98 12.41 Induction of apoptosis;
mRNA processing
[69, 70]
Identification of six genes with consistently increased transcript levels in two regions at two ages
Table 2 qPCR analysis shows Glo1 transcript levels to be ubiquitously and persistently increased in alpha-synuclein-deficient mouse brain
Brain region Age Fold expression change (KO versus WT) p value
Striatum 19 months ?2.73 (±0.33) 0.0013**
Brainstem 6 months ?1.95 (±0.04) 0.0008***
Midbrain 6 months ?1.74 (±0.07) 0.0033**
Cortex 6 months ?1.60 (±0.08) 0.0090**
Cerebellum 6 months ?1.83 (±0.13) 0.0153*
Left brain hemisphere 7 days ?2.17 (±0.10) \0.0001***
Expression levels of the transcript for TATA binding protein (Tbp) were used for normalization of Glo1 transcript levels. Fold expression
changes are presented as mean ± SEM and significant differences were highlighted with asterisks (*p \ 0.05, **p \ 0.01, and ***p \ 0.001;
t test). n = 3–5 animals/genotype
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the concentration of methylglyoxal (MG; Fig. 2e, f) was
significantly elevated in both regions (27% in brainstem/
midbrain and 34% in cortex; p \ 0.05), and higher in the
brainstem/midbrain than in cortex of WT mice (1.47 ±
0.16 vs. 0.30 ± 0.06 nmol/g wet weight; p \ 0.001). The
concentrations of the non-GLO1 dicarbonyl 3-deoxyglu-
cosone (3-DG; Fig. 2g, h) were unchanged in KO mice,
being lower in the cortex (0.11 ± 0.03 nmol/g wet weight)
than in the brainstem/midbrain of WT mice (0.19 ±
0.06 nmol/g wet weight; p \ 0.05). Thus, both GLO1
activity and MG levels were significantly elevated in both
brain regions of old KO mice.
GLO1 effects on spontaneous locomotor behavior
GLO1 upregulation was previously found to influence
behavior in mice. Investigations into biomarkers of anxiety
traits observed increased expression levels of GLO1 in
brains of mouse strains particularly susceptible to anxiety,
and showed that lentiviral transduction of GLO1 in the
cingulate cortex induced the mice to spend 16% more time
close to the wall of an open field chamber [39]. Therefore,
we used the open field paradigm to determine whether
similar anxiety-related changes of movement were detect-
able in SNCA-deficient mice. Indeed, the documentation of
spontaneous motor activity over a 5-min period in old
animals demonstrated a 28% significantly reduced will-
ingness to leave the area close to the walls and roam in the
unprotected center of the open field chamber (Fig. 3).
Thus, GLO1 upregulation in SNCA-deficient mice modu-
lated animal behavior in a previously reported manner.
Glucose stress marker FL is elevated in both brain
regions, three MG-dependent proteome modifications
are increased in brainstem/midbrain in spite of GLO1
upregulation
Analysis of protein damage by glycation, oxidation, and
nitration in WT and KO mice showed increased early
glycation of brainstem/midbrain and cortex proteins.
Fructosyl-lysine (FL) residue content was increased 92 and
78% in brainstem/midbrain and cortex, respectively, of KO
mice with respect to WT controls (Table 3), suggesting
elevated glucose stress throughout the brain. With regard to
GLO1-dependent AGEs formation, there was a small
increase in CML residue content (15%) and greater
increases in CMC residue (157%) and CEL residue (32%)
contents in the brainstem/midbrain of KO versus WT mice,
suggesting AGE-formation to exhibit tissue-specificity due
to additional factors. For oxidative markers, there was only
a minor decrease of dityrosine (DT) residue content of
brainstem/midbrain protein in KO mice with respect to WT
controls (-26%), indicating the glycation stress to be
insufficient to elicit major pathological effects. For protein
nitration, 3-nitrotyrosine (3-NT) residues were quantita-
tively low but increased 115% in brainstem/midbrain of
KO versus WT mice (Table 3). Thus, tissue-specific factors
in the brainstem/midbrain appear to mediate a specific
increase of GLO1-dependent AGE formation and protein
nitration in spite of apparently ubiquitous glucose toxicity,
MG and GLO1 induction.
Discussion
We undertook a hypothesis-free approach to elucidate the
physiological roles of the presynaptic protein alpha-syn-
uclein. We found SNCA ablation to have a prominent
effect within the mouse brain transcriptome on GLO1
induction and to enhance markers of protein glycation.
GLO1 is an enzyme with ubiquitous expression in all cell
types and cytosolic location, which is conserved with 50%
amino acid identity from microorganisms and plants to
mammals [40]. Interacting with the cofactor glutathione,
GLO1 is important for the detoxification of the dicarbonyl
compounds glyoxal and methylglyoxal which are formed
by the degradation of triosephosphates mainly during gly-
colysis, but also during lipid peroxidation and other cellular
processes. GLO1 transcript levels are induced by its sub-
strates, as was shown by administering glyoxal to the
drinking water of rats or MG into the cerebrospinal fluid of
Fig. 1 Elevation of GLO1 protein levels in striatum of alpha-
synuclein-deficient mice. a Immunoblot analysis revealed b significant
elevated GLO1 protein levels (3.26 ± 0.32-fold; n = 5/genotype,
p = 0.0003) in the striatum of KO mice at old age (19 months) in
comparison with corresponding WT controls. Protein expression
levels of beta-actin were used for normalization of GLO1 protein
levels and to confirm equal protein loading. Data are presented as
mean ± SD and significant differences were highlighted with aster-
isks (***p \ 0.001; t test). n = 5 animals/genotype
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mice [41, 42]. Thus, GLO1 protects cells against dicar-
bonyl damage to proteins and nucleotides [43], having a
significant role in countering proteome damage in hyper-
glycemia and aging [44, 45]. Under glucose stress
conditions, hexoses react mainly with lysine side chain
amino groups of proteins to form the early glycation adduct
FL, whereas the later glycation of proteins by the triose
metabolites glyoxal and methylglyoxal is directed mainly
to arginine residues with minor modification of lysine and
cysteine residues, forming AGEs with signaling function or
with toxic effects if in excess. In view of its protective role
against glucose toxicity, GLO1 has been extensively
studied in diabetes mellitus models [45].
In SNCA-deficient brain tissue, the upregulation of
GLO1 expression occurs with regard to transcript levels,
protein levels and enzymatic activity consistently in all
Fig. 2 Elevated GLO1 activity
and dicarbonyl stress in alpha-
synuclein-deficient mouse brain.
Brainstem/midbrain and cortex
from old WT and KO mice were
analyzed for GLO1 enzymatic
activity (a, b) and dicarbonyl
stress markers glyoxal (c, d),
methylglyoxal (e, f) and the
non-GLO1 dependent
dicarbonyl 3-DG (g, h). Data
are presented as mean ± SD
and significant differences were
highlighted with asterisks
(*p \ 0.05 and ***p \ 0.001;
t test). n = 6 animals/genotype
Fig. 3 Reduced exploratory motor activity in alpha-synuclein-
deficient mice. Automatic recording of the spontaneous movement
of untrained old mice over 5 min by infrared beams and calculating
the time spent within the 5 9 5 cm chamber center versus the
margins showed a significant preference of KO animals to spend time
in the ‘‘protected’’ environment close to the walls (n = 22 WT vs.
n = 28 KO). Data are presented as mean ± SD and significant
differences were highlighted with asterisks (*p \ 0.05; t test)
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regions and at all ages documented. This was linked to a
ubiquitous increase in MG concentration. The relative flux
of MG formation is expected to be proportional to the
product of GLO1 activity x steady-state MG concentration.
On this basis, the flux of MG has likely increased *two-
fold in the brainstem/midbrain and *threefold in the
cortex of KO with respect to WT mice. Furthermore, the
GLO1 induction was accompanied by a deficit in explor-
atory movement activity, as observed previously in
anxiety-biomarker studies in rodents. These data are con-
sistent at genetic, biochemical, and behavioral levels and
indicate that the transcriptional upregulation of GLO1
responds to increased formation of MG in the brain with
subsequent changes in neural function and behavior.
The glucose-derived early glycation adduct FL content
of protein was also increased ubiquitously in KO mouse
brain. This might be caused by increased neuronal glucose
concentration, impaired protein turnover or decreased
repair of FL residues by fructosamine 3-phosphokinase.
The brain is high in expression of this enzyme and hence
low in FL residue content [46, 47]. KO mice might have
impaired repair of FL residues. Alternatively, a ubiquitous
elevation of brain glucose levels and glycolytic activity
would explain the increased FL levels and would also
explain the GLO1 upregulation through substrate induction.
The loss-of-function of alpha-synuclein may produce
increased glucose entry and utilization. Although alpha-
synuclein was not previously implicated in glucose
metabolism, this interpretation of the GLO1 upregulation is
supported by the previously published transcriptional
downregulation of Rmnd5a in SNCA-KO brain tissue [38].
Its well-studied yeast ortholog Rmd5 is known to negatively
regulate gluconeogenesis through an ubiquitination of
fructose-1,6-bisphosphatase (FBPase). The notion of ele-
vated glucose flux is compatible with previous observations
that SNCA deficiency confers resistance to inhibitors of
respiration [48–52], since increased ATP-generation
through glycolysis would decrease cellular dependence on
mitochondrial respiration and might diminish the ROS
burden while enhancing AGE formation. Thus, a role of
alpha-synuclein for glucose utilization in brain tissue would
provide a credible explanation for our findings.
The increased AGEs in KO mouse brains were those
formed by GLO1 substrates (CMC and CML formed from
glyoxal and CEL formed from methylglyoxal; CML is also
formed by oxidative degradation of FL residues). This
elevation occurred as a consequence of increased MG
concentration in spite of increased GLO1 activity, sug-
gesting that KO mice have enhanced flux of formation of
glyoxal and methylglyoxal. Thus, the upregulation of GLO1
activity provides an imperfect protection of the proteome
against the dicarbonyl stress. Surprisingly, there was no
increase in oxidative damage in the KO mice as indicated by
lack of increase in methionine sulfoxide (MetSO), DT and
N-formylkynurenine (NFK) residues. This lack of oxidative
stress is in keeping with the lack of neurodegeneration
and the normal lifespan of SNCA-KO mice. There was,
however, increased 3-NT in brainstem/midbrain sections
suggesting there is increased protein nitration damage in this
region. In the absence of oxidative stress, 3-NT may be
Table 3 Markers of protein damage in brainstem/midbrain and cortex of old alpha-synuclein-deficient and wild-type mice
Type of modification Analyte Brainstem/midbrain Cortex
WT KO WT KO
Fructosamine FL 8.57 ± 3.55 16.48 ± 5.39* 9.2 ± 3.1 16.4 ± 2.8**
AGE CML 0.101 ± 0.008 0.116 ± 0.014* 0.144 ± 0.043 0.132 ± 0.019
CMA 0.156 ± 0.034 0.155 ± 0.038 0.124 ± 0.049 0.129 ± 0.031
CMC 0.134 ± 0.035 0.345 ± 0.174* 0.398 ± 0.127 0.428 ± 0.075
CEL 0.067 ± 0.012 0.097 ± 0.022* 0.061 ± 0.018 0.076 ± 0.018
MOLD 0.030 ± 0.016 0.057 ± 0.028 0.161 ± 0.084 0.195 ± 0.079
G-H1 0.089 ± 0.060 0.112 ± 0.087 0.075 ± 0.040 0.075 ± 0.036
MG-H1 0.765 ± 0.166 0.772 ± 0.117 0.382 ± 0.077 0.418 ± 0.096
3DG-H 0.247 ± 0.040 0.299 ± 0.059 0.325 ± 0.087 0.253 ± 0.032
Pentosidine 0.0032 ± 0.0003 0.0036 ± 0.0008 0.0032 ± 0.0019 0.0034 ± 0.0005
Oxidation MetSO 17.7 ± 3.2 15.1 ± 1.3 15.5 ± 2.2 14.6 ± 1.3
DT 0.018 ± 0.001 0.013 ± 0.005* 0.011 ± 0.001 0.012 ± 0.002
NFK 0.506 ± 0.137 0.629 ± 0.104 0.350 ± 0.059 0.448 ± 0.145
Nitration 3-NT 0.0028 ± 0.0006 0.0059 ± 0.0015*** 0.0036 ± 0.0004 0.0046 ± 0.0022
Data for FL, CML, CEL, CMC, MOLD, and PENT are mmol/mol lys, for G-H1, MG-H1, 3DG-H and CMA are mmol/mol arg, for MetSO are
mmol/mol met, for DT and 3-NT are mmol/mol tyr and for NFK, mmol/mol trp. Data are presented as mean ± SD and significant differences
were highlighted with asterisks (*p \ 0.05 and ***p \ 0.001; t test). n = 6 animals/genotype
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formed e.g., by inflammation induced expression of iNOS.
Nitrosative stress contributes to pathology in neurodegen-
erative diseases via 3-NT- mediated nitration of proteins and
lipids [53]. Interestingly, the significant elevation of AGEs
and of 3-NT both were observed specifically in the brain-
stem/midbrain in spite of the ubiquitous elevation of FL,
MG, and GLO1, suggesting additional tissue specific factors
to modulate protein damage. In summary, the ubiquitous
transcriptional upregulation of GLO1 expression was
insufficient in the brainstem/midbrain to prevent glycation
damage and nitrosative stress.
Glo1 transcript upregulation had not been significant in
a previous transcriptome profiling effort of SH-SY5Y
neuroblastoma cells with SNCA knock-down to about 40%
protein level [54], but the use of DMEM with high glucose
supply for mutant and control tumor cells may have pre-
cluded this observation. Our findings are clearly important
to elucidate the physiological role of alpha-synuclein in
brain. Whether they are also relevant for PD pathology
remains unclear at present and is beyond the scope of this
manuscript. Since the loss-of-function of alpha-synuclein
results in GLO1 upregulation in mouse brain, any alpha-
synuclein gain-of-function in vulnerable areas of PD
patient brain might be expected to result in a GLO1
downregulation. Consistent with this notion, a downregu-
lation of GLO1 (also named lactoylglutathione lyase)
together with downregulations of four mitochondrial
OXPHOS and 3 peroxiredoxins was observed in the mid-
brain of Parkin-KO mice which model the autosomal
recessive PARK2 variant of PD [55]. Thus, alterations of
GLO1 expression and possibly glucose flux may occur in
parallel to the mitochondrial dysfunction characteristic of
PD. Altered GLO1 levels were the only significant
expression change upon genome-wide transcriptome pro-
filing in brain tissue from tau mouse mutants modeling
Alzheimer’s disease [56]. AGEs are capable of inactivating
and crosslinking proteins, thus enhancing polymerization
e.g., of beta-amyloid [57, 58]. Our findings about a role of
alpha-synuclein KO for protein glycation is therefore
consistent with published data that SNCA ablation
increases amyloid plaque accumulation and disease pro-
gression in transgenic mouse models of AD without
affecting amyloid-beta levels or onset age [59]. Thus, the
regulation of GLO1 by alpha-synuclein appears relevant
also in the context of neurodegenerative diseases.
At present, it remains unclear whether alpha-synuclein
deficiency exerts a direct or indirect regulation of glucose
metabolism. It would be interesting now (1) to assess the
flux of glucose through anaerobic glycolysis and through
the pentose phosphate pathway in these mice, since this
might provide a basis to pharmacologically modulate this
flux and reduce triosephosphate intermediate burden [60],
(2) to study the consequent protein o-glycosylation, since
in particular o-GlcNAc formation is known as a key reg-
ulator in diabetes mellitus and Alzheimer’s disease [61],
(3) to determine whether the induction of AGEs affects the
levels of RAGE, since this receptor has a key signaling role
in inflammation and protein aggregation diseases [62].
In summary, we report ubiquitous glucose-dependent
cell stress and brainstem/midbrain-specific glycation and
nitrosative stress in spite of a protective induction of GLO1
throughout the brain of SNCA-deficient mice. As illus-
trated in Fig. 4, we propose that alpha-synuclein modulates
brain dicarbonyl metabolism (reflected by the enhanced
levels of MG and AGEs and increased GLO1 expression)
through an effect on glucose flux.
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